Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NYSE: KVUE

Kenvue Inc.

Consumer Defensive | Household & Personal Products
$18.95 as of 2026-09-04 07:09 UTC
Market Cap$36.4B
Volume18.57M
EPS (TTM)$0.76

Kenvue Inc. (NYSE: KVUE) is a $36.4B household & personal products company trading at $18.95 — 24.9× trailing earnings, yielding 4.34%. Figures from SEC EDGAR and market feeds; updated 2026-09-04 07:09 UTC.

52-Week Range
Low $16.66High $20.13

What Kenvue Inc. does

Kenvue is a global consumer health company that was separated from Johnson & Johnson and became an independent public company in 2023. The company sells over-the-counter medicines and health-related products through a portfolio of well-known brands including Tylenol, Aveeno, Neutrogena, and Listerine across more than 165 countries. Its products are organized into three segments: Self Care, Skin Health and Beauty, and Essential Health, allowing the company to serve consumers in daily health and wellness routines.

Summarized from Kenvue Inc.’s SEC filings · Read the filing ↗

Key facts

Quote
Price$18.95
Market cap$36.4B
Volume18.57M shares
52-week range$16.66 – $20.13
Valuation
P/E (TTM)24.93×
EV/EBITDA12.40×
EPS (TTM)$0.76
Dividend yield4.34%
Price/book3.38×
Return on equity13.66%
Debt/equity0.13
Returns
52-week return+13.7%

Revenue, margins & earnings

FY2021 Net income: $2.08BFY2021 Taxes & interest: $842MFY2021 Operating expenses: $5.50BFY2021 Cost of revenue: $6.63B$15.1BFY2021FY2022 Net income: $2.06BFY2022 Taxes & interest: $611MFY2022 Operating expenses: $5.61BFY2022 Cost of revenue: $6.67B$14.9BFY2022FY2023 Net income: $1.66BFY2023 Taxes & interest: $848MFY2023 Operating expenses: $6.13BFY2023 Cost of revenue: $6.80B$15.4BFY2023FY2024 Net income: $1.03BFY2024 Taxes & interest: $811MFY2024 Operating expenses: $7.12BFY2024 Cost of revenue: $6.50B$15.5BFY2024FY2025 Net income: $1.47BFY2025 Taxes & interest: $944MFY2025 Operating expenses: $6.38BFY2025 Cost of revenue: $6.33B$15.1BFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-04
  • 2026-08-04Dasgupta AnindyaGroup President APACM16,418—
  • 2026-08-04Dasgupta AnindyaGroup President APACM-16,418—
  • 2026-07-01ALLISON RICHARD E JRA1,413—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Kenvue Inc. do?

Kenvue is a global consumer health company that was separated from Johnson & Johnson and became an independent public company in 2023.

What is KVUE's valuation?

KVUE trades at $18.95, 24.93× trailing earnings, 12.40× EV/EBITDA, as of 2026-09-04. It carries a 4.34% dividend yield.

When did KVUE last file with the SEC?

Kenvue Inc.'s most recent SEC filing on record is a 8-K filed 2026-05-22. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-09-04 07:09 UTC. This page is also available as JSON at /api/data?ticker=KVUE and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for KVUE and 5,000+ tickers.

Create a free account — keep KVUE
For your agent
GET /api/data?ticker=KVUE

This page as JSON via rel="alternate" · REST API docs · MCP server (59 tools) · llms.txt